Blood Viscometer Market Segmentation:
End user Segment Analysis
The hospitals segment is projected to account for a 65% share of the global blood viscometer market by the end of 2035. Blood viscometers in hospitals have a widespread use case to precisely and rapidly obtain blood type information such as blood group typing, thus enabling healthcare providers to make prompt and accurate decisions. According to a July 2022 report by the National Library of Medicine, high-shear BV (eHSBV) and low-shear BV were associated with elevated in-hospital mortality, respectively 36.0% and 7.0% rise in death. COVID-19 sparked abnormal blood rheology leading to thrombotic complications and endothelial dysfunction. Whole blood viscosity (WBV) has been identified as a clinically validated predictor of cardiovascular risks and a measure of blood rheology in hospital settings.
Type Segment Analysis
The rotational viscometer segment in blood viscometer market is anticipated to hold the largest revenue share of about 68% during the forecast period. Rotational viscometers are pivotal in bio-medical labs and clinical studies to test glycerol–water mixtures with various densities using optical coherence tomography (OCT) measurement method. It is also a standard treatment procedure and therapeutic apheresis for HVS management, among patients with hyper-viscosity of the plasma and immunoglobulin reduction. Rotational viscometers have resulted in a shift from conventional rituximab- and alkylator-based, and purine nucleoside analog-based therapies, which usually take months to show the best response.
Our in-depth analysis of the global blood viscometer market includes the following segments:
|
Type |
|
|
End user |
|
